Journal of Thrombosis and Thrombolysis

Papers
(The H4-Index of Journal of Thrombosis and Thrombolysis is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Neutrophil extracellular traps and thrombosis in COVID-19188
Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review64
Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients54
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum42
Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting41
Incidence of thrombotic complications in COVID-1940
Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus40
Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-1940
Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series38
Pulmonary thrombosis in Covid-19: before, during and after hospital admission36
Major bleeding complications in critically ill patients with COVID-19 pneumonia32
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis31
SARS-CoV-2 infection and thrombotic complications: a narrative review29
COVID-19 and its sequelae: a platform for optimal patient care, discovery and training28
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage28
Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation27
Serotonin: a platelet hormone modulating cardiovascular disease27
A comprehensive review of vascular complications in COVID-1926
Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy25
Thrombosis in VEXAS syndrome25
External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-1923
Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-1922
0.063209056854248